BlackRock acquired 1.34M MapLight Therapeutics shares worth $40.3M. That's 0.00% of their equity portfolio (2536th largest holding). The investor owns 174.30% of the outstanding MapLight Therapeutics stock. The stake costed the investor $24.4M, netting the investor a gain of 65% so far.